First line therapy with Fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukemia

Leukemia and Lymphoma

Volumn 40, Issue 3-4, 2001, Pages 305-313

  Clavio, M ^a   Gatto, S ^a   Beltrami, G ^a   Cerri, R ^a   Carrara, P ^a   Pierri, I ^a   Canepa, L ^a   Miglino, M ^a   Balleari, E ^a   Masoudi, B ^a   Damasio, E ^a   Ghio, R ^a   Sessarego, M ^a   Gobbi, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

AML induction therapy; Fludarabine combinations; Karyotype; MDS AML; Therapy related AML

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; FOLLOW UP; GRANULOCYTE; HUMAN; HUMAN CELL; KARYOTYPE; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE; TIME; TREATMENT OUTCOME;

EID: 0035035504     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109057929     Document Type: Article

References (34)

1. Biology and therapy of secondary leukemias
2. AML associated with previous cytotoxic therapy or myeloproliferative disorders: Results from the MRC's 9th AML trial
3. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome
4. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
5. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
6. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myeloid leukemia
7. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with cytarabine without granulocyte colony-stimulating factor
8. FLAG (Fludarabine + High dose cytarabine + G-CSF) an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias
9. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor -risk myelodysplastic syndromes and acute myeloid leukemia
10. Randomized phase II study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-trans Retinoic Acid ± Granulocyte Colony - Stimulating Factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
11. Fludarabine inhibits DNA replication: A rationale for its use in the treatment of acute leukemias
12. Fludarabine: Pharmacokinetics, mechanisms of action and rationales for combination therapies
13. Acute myeloid leukemia in the elderly: Assessment of multidrug resistence (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study
14. Treatment of therapy-related leukemia and myelodysplastic syndrome
15. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the Research and Treatment in Cancer (EORTC-LCG)
16. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy related acute myelogenous leukemia
17. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy
18. The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS
19. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
20. Effect of diagnosis (Refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia on outcome of AML-type chemotherapy
21. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS
22. Cytogenetics for detection of MRD in acute myeloblastic leukemia
23. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission
24. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
25. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)
26. A double blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031)
27. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia
28. New agents for the treatment of acute myelogenous leukemia, focus on topotecan and retinoids
29. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
30. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia
31. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes
32. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy related acute myelogenous leukemia
33. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
34. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases